Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 7/20 | 1.00 |
| ▸ | LPL | P06858 | 6/20 | 1.00 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.61 |
| ▸ | MGLL | Q99685 | 1/20 | 0.61 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28980699 | 0.98 | LIPG (1.00) | LIPGLPLTRPV1MGLLENPP2 | |
| SCHEMBL28980647 | 0.98 | LIPG (1.00) | LIPGLPLTRPV1MGLLENPP2 | |
| SCHEMBL28980712 | 0.98 | LIPG (1.00) | LIPGLPLTRPV1MGLLENPP2 | |
| SCHEMBL28980689 | 0.98 | LIPG (1.00) | LIPGLPLTRPV1MGLLENPP2 | |
| SCHEMBL3146386 | 0.98 | LIPG (1.00) | LIPGLPLTRPV1MGLLENPP2 | |
| SCHEMBL3138179 | 0.95 | LPL (0.90) | LIPGLPLTRPV1MGLLENPP2 | |
| SCHEMBL1421621 | 0.87 | LPL (0.77) | LIPGLPLTRPV1MGLLENPP2 | |
| SCHEMBL30445243 | 0.84 | LPL (0.75) | LIPGLPLTRPV1MGLLENPP2 | |
| SCHEMBL18126523 | 0.84 | LPL (0.75) | LIPGLPLTRPV1MGLLENPP2 | |
| SCHEMBL10456885 | 0.82 | LPL (0.69) | LIPGLPLTRPV1MGLLCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115928264-A | Preparation method of metal-containing near-stoichiometric continuous silicon carbide fiber | 湖南泽睿新材料有限公司 | 2023-04-07 | — | — | CN | claimed |
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-28 | — | — | US | disclosed |
| CN-115928264-A | Preparation method of metal-containing near-stoichiometric continuous silicon carbide fiber | 湖南泽睿新材料有限公司 | 2023-04-07 | — | — | CN | disclosed |
| EP-3390571-B1 | CINNAMIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2021-03-31 | — | — | EP | disclosed |
| US-10465115-B2 | Cinnamic acid derivatives | MERCK PATENT GMBH (DE) | 2019-11-05 | — | — | US | disclosed |
| US-20180371318-A1 | CINNAMIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2018-12-27 | — | — | US | disclosed |
| EP-3390571-A2 | CINNAMIC ACID DERIVATIVES | Merck Patent GmbH (DE) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017102053-A2 | CINNAMIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | WO | disclosed |
| EP-2337784-A1 | MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-06-29 | — | — | EP | disclosed |
| WO-2010036871-A1 | MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-01 | — | — | WO | disclosed |
| US-6448238-B1 | BORONIC ACIDS USED WITH BETA-LACTAM ANTIBIOTICS, SUCH AS AMOXICILLIN OR CEFTAZIDIME, TO TREAT BETA-LACTAM ANTIBIOTIC RESISTANT BACTERIAL INFECTIONS | NORTHWESTERN UNIVERSITY | 2002-09-10 | — | — | US | disclosed |
| US-6417174-B1 | BACTERICIDES | NORTHWESTERN UNIVERSITY | 2002-07-09 | — | — | US | disclosed |
| US-6184363-B1 | Inhibitors of β-lactamases and uses therefor | NORTHWESTERN UNIVERSITY | 2001-02-06 | — | — | US | disclosed |
| EP-1009415-A4 | INHIBITORS OF $g(b)-LACTAMASES AND USES THEREFOR | UNIV NORTHWESTERN (US) | 2000-10-25 | — | — | EP | disclosed |
| EP-1009415-A1 | INHIBITORS OF $g(b)-LACTAMASES AND USES THEREFOR | NORTHWESTERN UNIVERSITY (US) | 2000-06-21 | — | — | EP | disclosed |
| US-6075014-A | BACTERICIDES | NORTHWESTERN UNIVERSITY (US) | 2000-06-13 | — | — | US | disclosed |
| WO-1998056392-A1 | INHIBITORS OF β-LACTAMASES AND USES THEREFOR | NORTHWESTERN UNIVERSITY (US) | 1998-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180371318-A1 | CINNAMIC ACID DERIVATIVES | RCC1, LSS, C1S | LIPG 2188/4885LPL 2000/4885TRPV1 1090/4885 |
| US-10465115-B2 | Cinnamic acid derivatives | RCC1, LSS, C1S | LIPG 2191/4885LPL 2055/4885TRPV1 1107/4885 |
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | DHODH, CD38, DPYD | LIPG 1464/4885LPL 913/4885TRPV1 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.